Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-19
2011-04-19
Nolan, Jason M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S430000, C514S475000, C546S279700, C549S090000, C549S556000
Reexamination Certificate
active
07928127
ABSTRACT:
The present invention provides novel compounds of formulas I-IX, as described herein. Also provided are compositions of compounds of formulas I-IX, methods of making compounds of formulas I-IX, and methods of using compounds of formulas I-IX. The compounds of the invention can be used to inhibit matrix metalloproteinases, and are useful to treat conditions and diseases associated therewith.
REFERENCES:
patent: 2949474 (1960-08-01), Murdoch et al.
patent: 2965651 (1960-12-01), Kosmin et al.
patent: 3222326 (1965-12-01), Brodoway
patent: 4797218 (1989-01-01), Steinberg et al.
patent: 5288722 (1994-02-01), Kishimoto et al.
patent: 5981763 (1999-11-01), Garapon et al.
patent: 6703415 (2004-03-01), Mobashery et al.
patent: WO-95/35275 (1995-12-01), None
patent: WO-97/18231 (1997-05-01), None
patent: WO-98/33788 (1998-08-01), None
patent: WO-2006125208 (2006-11-01), None
Schafer et al. (Drug Discovery Today 2008, 13 (21/22), 913-916).
Horig et al. Journal of Translational Medicine 2004, 2(44).
Catterall et al., Arthritis Research & Therapy 2003, 5(1), 12-24.
“Application Serial No. PCT/US2006/019656, Int'l Preliminary Examination Report Mailed Feb. 20, 2009” 6 pgs.
“International Application Serial No. PCT/US06/19656, International Search Report mailed Oct. 2, 2006”, 6 pgs.
“International Application Serial No. PCT/US06/19656, Written Opinion mailed Oct. 2, 2006”, 5 pgs.
Beckett, R. Paul, et al., “Recent Advances in Matrix Metalloproteinase Inhibitor Research”,Drug Discovery Today, 1(1), (Jan. 1996), 16-26.
Brew, K., et al., “Tissue Inhibitors of Metalloproteinases: Evolution, Structure and Function”,Biochimica et Biophysica Acta, 1477(1-2), (Mar. 7, 2000), 267-283.
Brown, Stephen, et al., “Potent and Selective Mechanism-Based Inhibition of Gelatinases”,Journal of the American Chemical Society, 122(28), (Jul. 19, 2000), 6799-6800.
Bruce, Colleen, et al., “The effect of marimastat, a metalloprotease inhibitor, on allergen-induced asthmatic hyper-reactivity”,Toxicology and Applied Pharmacology 205, (2005), 126-132.
Bulychev, A., et al., “N-Sulfonyloxy-beta-lactam Inhibitors for beta-Lactamases”,Tetrahedron, 56(31), (Jul. 28, 2000), 5719-5728.
Dalberg, Kristina, et al., “Gelatinase A, Membrane Type 1 Matrix Metalloproteinase, and Extracellular Matrix Metalloproteinase Inducer mRNA Expression: Correlation with Invasive Growth of Breast Cancer”,World Journal of Surgery, 24(3), (Mar. 2000), 334-340.
Demedts, Ingel K, et al., “Matrix metalloproteinases in asthma and COPD”,Current Opinion in Pharmacology, (2005), 257-263.
Dumas, V., et al., “Expression of basement membrane antigens and matrix metalloproteinases 2 and 9 in cutaneous basal and squamous cell carcinomas”,Anticancer Research, 19(4B), (Jul.-Aug. 1999), 2929-2938.
Forget, Marie-Annick, et al., “Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis”,Canadian Journal of Physiology and Pharmacology, 77, (1999), 465-480.
Freskos, J., et al., “Discovery of a Novel Series of Selective MMP Inhibitors: Identification of the γ-Sulfone-Thiols”,Bioorganic&Medicinal Chemistry Letters, 9(7), (Apr. 5, 1999), 943-948.
Fridman, R., et al., “Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions”,Journal of Biological Chemistry, 267(22), (Aug. 5, 1992), 15398-15405.
Fridman, R., et al., “Expression of human recombinant 72 kDa gelatinase and tissue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme”,Biochemical Journal, 289( Pt 2), (Jan. 15, 1993), 411-416.
Greenwald, R A., et al., “Thirty-six Years in the Clinic without an MMP Inhibitor: What Hath Collagenase Wrought?”,Annals of the New York Academy of Sciences, 878, (Jun. 1999), 412-419.
Hasaneen, Nadia A, et al., “Cyclic mechanical strain-induced proliferation and migration of human airway smooth muscle cells: role of EMMPRIN and MMPs”,The FASEB Journal, (Sep. 2005), 1507-1509.
Ikeijiri, et al., “Design, Synthesis, and Evaluation of a Mechanism-Based Inhibitor for Gelatinase A”,J.Org Chem., 70, (2005), 5709-5712.
Knight, C G., “Fluorimetric assays of proteolytic enzymes”,Methods in Enzymology, 248, (1995), 18-34.
Leath, Thomas M, et al., “Novel and emerging therapies for asthma”,DDTvol. 10, No. 23/24, (Dec. 2005), 1647-1655.
Lee, Mijoon, et al., “Synthesis of Chiral 2-(4-Phenoxyphenylsulfonylmethyl)thiiranes as Selective Gelatinase Inhibitors”,Organic Lettersvol. 7, No. 20, (2005), 4463-4465.
Lim, Taek, et al., “A convenient Synthesis of a Selective Gelatinase Inhibitor as an Antimetastatic Agent”,J. Org. Chem. 69, (2004), 3572-3573.
Marshall, D.C.L., et al., “Introduction of matrix metalloproteinase-2 in human immunodeficiency virus-1 glycoprotein 120 transgenic mouse brains”,Neuroscience Letters 254, (1998), 97-110.
Massova, Irina, et al., “Matrix Metalloproteinases: Structures, Evolution, and Diversification”,FASEB Journal. 12(12), (Sep. 1998), 1075-1095.
Massova, Irina, et al., “Structural Insights into the Catalytic Domains of Human Matrix Metalloprotease-2 and Human Matrix Metalloprotease-9: Implications for Substrate Specificities”,Journal of Molecular Modeling, 3(1), (Jan. 1997), 17-30.
McMillan, Sarah J, et al., “Matrix Metalloproteinase-9 Deficiency Results in Enhanced Allergen-Induced Airway Inflammation”,The Journal of Immunology 172, (2004), 2586-2594.
Michaelides, M. R., et al., “Recent advances in matrix metalloproteinase inhibitors research”,Current Pharmaceutical Design, 5(10), (Oct. 1999), 787-819.
Misse, Dorothee, et al., “HIV-1 glycoprotein 120 induces the MMP-9 cytopathogenic factor production that is abolished by inhibition of the p38 mitogen-activated protein kinase signaling pathway”,Blood, vol. 98, No. 3, (Aug. 1, 2001), 541-547.
Morgunova, Ekaterina, et al., “Structure of Human Pro-Matrix Metalloproteinase-2: Activation Mechanism Revealed”,Science, 284(5420), (Jun. 4, 1999), 1667-1670.
Nelson, Amy R., et al., “Matrix Metalloproteinases: Biologic Activity and Clinical Implications”,Journal of Clinical Oncology, 18(5), (Mar. 1, 2000), 1135-1149.
Olson, Matthew W, “Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1”,Journal of Biological Chemistry, 275(4), (Jan. 28, 2000), 2661-2668.
Pyke, C., et al., “Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization”,Cancer Research, 52(5), (Mar. 1, 1992), 1336-1341.
Salo, Tuula, et al., “Purification and Characterization of a Murine Basement Membrane Collagen-degrading Enzyme Secreted by Metastatic Tumor Cells”,Journal of Biological Chemistry258(5), (Mar. 10, 1983), 3058-3063.
Suryadevara, Radhika, et al., “Regulation fo Tissue Inhibitor of Metalloproteinase-1 by Astrocytes”,GLIAA 44, (2003), 47-56.
Tamura, Y., “Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2): N-Sulfonylamino Acid Derivatives”,Journal of Medicinal Chemistry, 41(4), (Feb. 12, 1998), 640-649.
Toft-Hansen, Henrik, et al., “Key Metalloproteinases Are Expressed by Specific Cell Types in Experimental Autoimmune Encephalomyelitis”,The Journal of Immunology, (2004), 5209-5218.
Vermaelen, Karim Y, et al., “Matrix Metalloproteinase-9-Mediated Dendritic Cell Recruitment into the Airways Is a Critical Step in a Mouse Model of Asthma”,The Journal of Immunology, (2003), 1016-1022.
Westermarck, Jukka, et al., “Regulation of M
Chang Mayland
Fridman Rafael
Ikejiri Masahiro
Lee Mijoon
Mobashery Shahriar
Clise, Billion & Cyr, P.A.
Haukaas Michael H.
Nolan Jason M
Notre Dame University
Wayne State University
LandOfFree
Inhibitors of matrix metallaproteinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of matrix metallaproteinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of matrix metallaproteinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2707792